Cambrian BioPharma is making a big move in the longevity biotech space with the launch of Amplifier Therapeutics. This clinical-stage company is focused on developing an AMPK activator that could potentially revolutionize the treatment of obesity. Just two months after their last pipeline company launch, Cambrian BioPharma is continuing to innovate and make strides in the field of longevity.
With a $26 million USD acquisition, Amplifier’s first clinical program – ATX-304 – is now in the hands of the biopharma experts at Amplifier. Led by James Hall, CEO of Betagenon, the team is now heading to the clinic to make strides in the medical world.
ATX-304 is a powerful pan-AMPK activator that helps to restore cellular energy levels and keep the body functioning optimally. When energy levels in the cell drop, AMPK is activated to draw sugar from the blood and mobilize fat to create energy. This natural process is especially important during exercise, fasting, or when oxygen supply is limited. Unfortunately, as we age, our bodies’ ability to activate AMPK weakens, making ATX-304 an invaluable supplement to help maintain healthy energy levels.
Activating AMPK could revolutionize the treatment of age-related illnesses, such as cardiovascular and kidney disease, diabetes and cancer. By stimulating the body to enter a fast burn metabolic state, akin to that seen after exercise, the potential health benefits could be far reaching. AMPK activation could be the key to unlocking a healthier, longer life.
James Peyer, CEO of Cambrian, stated that endurance and cardiovascular health are both improved with the use of their product. He emphasized that regular use can have a tangible impact on health and well-being.
You can achieve fast and lasting weight loss and fat reduction, with no loss of muscle or even muscular gain. Not only that, but the functioning of your organs, from your liver to your kidneys, will also improve! Start your journey to a healthier, slimmer you today!
The core vision of the company is to increase humanity’s health span, and they are utilizing age and metabolic-related disease to get their drug through to commercialization as a “reactive medicine” as the first step in achieving this goal. Ultimately, they are striving to reach a status of preventative medicine.
A Holy Grail Target
In October 2022, Eli Lilly and Nimbus Therapeutics joined forces in a licensing deal worth close to $500 million, reflecting the pharmaceutical giants’ strong belief in the potential of AMPK activation. Nimbus Therapeutics is tasked with identifying isoform-selective small molecule AMPK activators, setting the stage for new ground-breaking treatments.
In a remarkable show of confidence, Pfizer Ventures invested in Nimbus just a month after the company secured a $125 million funding round. The move is seen as a significant endorsement of the company’s potential and a major boost to its future prospects.
Jeb Keiper, CEO of Nimbus, hailed AMPK activation as a “holy grail target in cellular energy balance” upon the company launch, a view shared by his colleague Peyer. Keiper took to Twitter to share his enthusiasm for the discovery, sparking a conversation around the revolutionary importance of AMPK activation.
Nimbus’s candidate is still in the preclinical stage, but Amplifier’s is ready for the clinic! This year, Amplifier is embarking on an exciting Phase Ib trial which is slated to begin later in 2023. The clinical trial will explore the potential of Amplifier’s candidate to treat metabolic dysfunction, without targeting a specific disease. It’s sure to be an exciting journey as Amplifier’s candidate takes its first steps into the clinic!
The team behind the innovative new medical technology has a plan to launch trials for multiple indications, with a few great ideas in terms of target diseases already in the works. Although the specifics of the diseases they plan to target are still under wraps, the team is excited to start trials and bring their technology to the world.
The obesity space has been abuzz with the emergence of new treatments, such as Novo Nordisk’s Wegovy, a GLP-1 agonist that suppresses appetite through inducing satiety. However, Peyer’s AMPK activator takes a different approach, instead causing the body to mimic the effects of exercise.
If we continue to see positive results from this drug, we could potentially have a healthier alternative to GLP-1 drugs that could lead to sustainable weight loss. This could revolutionize the way we approach weight loss, providing a more effective, healthier solution.
Morgan Stanley has boldly declared that the market for obesity treatments has the potential to become a true success story, predicting that it will surge to a staggering $54 billion by 2030. This would make it one of the most profitable categories of drugs ever seen.